In 2020, 58-year-old Viswanathan, recovering from a stroke, sought physiotherapy from an Ayurvedic practitioner, hoping to regain mobility. However, this therapy precipitated wounds on his leg. As a diabetic with an already weakened immune system this marked the starting of his battle with antimicrobial resistance (AMR).
After a 12 months of battling infections, he was given a last-resort antibiotic that broken his kidneys. Hospital-acquired infections additional sophisticated his situation, and finally, he succumbed to AMR in April 2021.
Antibiotics, identified to save hundreds of thousands of lives, at the moment are making headlines for the reverse motive. AMR happens when microorganisms like micro organism evolve to develop resistance in opposition to the very medicine designed to kill them. AMR contributed to 1.27 million deaths globally and in India precipitated 2,97,000 deaths in 2019 based mostly on a report by the Institute of Health Metrics and Evaluation (IHME), University of Wahington. The public well being impression of bacterial AMR has been vital. According to a research revealed in The Lancet, 1.91 million individuals may die instantly from AMR and eight.22 million deaths related to AMR may happen globally in 2050.
Overuse of antibiotics throughout sectors
A number one trigger for AMR is the misuse and overuse of antibiotics throughout varied sectors. While of the complete antibiotics produced, round 30% are used to deal with people, the relaxation are used in livestock, agriculture and aquaculture. In nations like India, promoting antibiotics with out prescription additionally contributes on a big scale to resistance. The current ban on utilizing colistinas a progress promoter in the poultry trade in India has made vital inroads in curbing resistant strains from rising.
The World Health Organization (WHO) has declared AMR as one of the prime 10 world well being threats.
A brand new antibiotic after 30 years
In its effort to tackle AMR, Mumbai-based pharmaceutical firm Wockhardt, with help from the Biotechnology Industry Research Assistance Council (BIRAC) has launched Nafithromycin marketed as ‘Miqnaf’ to deal with Community-Acquired Bacterial Pneumonia (CABP). It is a once-a-day, three-day therapy for CABP with a 97% success price. It is India’s first indigenously-developed antibiotic in its class. It was additionally the first antibiotic to be developed in the final 30 years, globally.
“Nafithromycin is a part of our overall drug discovery programme which we started about 25 years ago,” mentioned Habil Khorakiwala, founder-chairman, Wockhardt. “[While] Azithromycin and other drugs were there, there was no new drug coming [up] and resistance was developing on [the other] end”, he added. The drug was developed over a span of 15 years.
With gradual progress in analysis in the subject of antibiotics, no new medicine have been developed in the previous three a long time globally. “After the initial boom and the “golden age” of antibiotics (from 1940 to 1960), the subject was marked by a pointy decline in new antibiotic approvals for many years,” mentioned Tomislav Mestrovic, affiliate affiliate professor of Health Metrics Sciences, at IHME, responding to questions by way of mail.
It is not any surprise then that with the improvement of Nafithromycin, India has reached a milestone given it has the highest burden of bacterial infections.
Gaps in healthcare system
While scientific developments like Nafithromycin are promising, additionally it is necessary for us to acknowledge the gaps inside India’s healthcare system that forestall efficient therapy in opposition to AMR.
Vysakh, Mr. Viswanathan’s son, a PhD scholar in Poland, mentioned a communication hole exists between medical professionals and the affected person’s relations. A lapse he believes the medical group additionally wants to tackle is the high quality of gear getting used. “Another pitfall that happens is diagnostic issues,” he identified. “It took at least one week to get a proper antibiogram delivered and to figure out [which] bacteria is causing infection and to [administer] the specific antibiotic. So this was a big problem”. He additionally added that there was a difficulty of accountability inside the system.
Vysakh’s household’s plight is sadly a standard situation throughout the healthcare system. “Understaffing of healthcare professionals combined with high patient loads makes it difficult to ensure adherence to best stewardship practices,” mentioned Dr. Mestrovic whereas talking about the key challenges India faces in implementing efficient antimicrobial stewardship throughout its healthcare community.
Apart from these issues, India additionally faces the added problem of self-medication by individuals, promoting of antibiotics with out prescriptions and lack of a correct regulatory framework. “[In] a lot of low-to-middle income countries you can go to a pharmacy and they will give you an antibiotic without any prescription,” mentioned François Franceschi, head of asset analysis and improvement and severe bacterial infections mission chief, Global Antibiotic Research & Development Partnership (GARDP), as he recalled his expertise at a pharmacy in Mumbai.
Despite antibiotics being pharmaceuticals in India they’re bought over-the-counter, contributing considerably to the resistance downside. “Part of the action plans that [are] trying to be implemented in many countries is [to] stop letting people buy antibiotics without prescription. That’s a big step and that should happen because otherwise, you know, you are fighting a battle that you’re going to lose”, mentioned Dr. Franceschi.
What the authorities is doing
The Indian authorities is engaged on a number of fronts to fight AMR together with establishing AMR surveillance networks, creating a National Action Plan and selling public consciousness. “The implementation of the National Action Plan on AMR in 2017 marked a key milestone in aligning the country’s efforts with the global strategy, and this is the right path forward,” mentioned Dr. Mestrovic.
Promoting public consciousness is a key facet that wants to be addressed from the very starting. It isn’t unusual to see individuals take antibiotics for a viral fever which isn’t solely ineffective however provides to resistance. “Public awareness about AMR remains low, leading to patient demand for antibiotics even when not needed which is not characteristic only for India, but much wider,” mentioned Dr. Mestrovic.
The urgent want to educate individuals about the risks of inappropriately utilizing antibiotics resonates with all the specialists in the subject.
Resistance is a pure phenomenon in microorganisms. But it occurs over time, via genetic modifications and diversifications. However, the widespread and extreme use of antibiotics throughout sectors has accelerated the course of. It is kind of pure to surprise then what the future of the new antibiotics which might be being developed seems like. “Long-term effectiveness of new antibiotics depends not only on scientific advancement, but also on responsible global stewardship from day one,” mentioned Dr. Mestrovic. “Patient education and public awareness are indispensable in the fight against AMR, especially when we are talking about the misuse and overuse of antibiotics.”
Education, innovation and regulation want to progress parallelly to curb AMR. “I think it’s very important that governments recognise that we need to do something now or we are going to be facing a problem that is much bigger in the future,” mentioned Dr. Franceschi. “We need to be multiple steps ahead of [pathogens]”.
The lengthy path forward
Nafithromycin is a begin and will probably be launched in the marketplace for a month in the coming few months. The improvement of antibiotics is an extended and resource-intensive course of. With an absence of elementary analysis in the subject, the improvement of antibiotics additionally takes a backseat. “Many large pharmaceutical companies exited the antibiotic space because the return on investment was too low compared to chronic disease drugs leading to what many called the “antibiotic innovation gap”, mentioned Dr. Mestrovic.
Institutions like Bangalore Bioinnovation Centre (BBC) and the Centre for Cellular and Molecular Platforms (C-CAMP) and corporations like Wockhardt, Orchid Pharma and Bugworks in India are amongst the few corporations that concentrate on antibiotic improvement.
Given the low return on funding, it’s largely small pharma corporations taking up the problem of creating new antibiotics throughout this disaster. And the path isn’t simple, particularly when it comes to medical trial approval by the Central Drugs Standard Control Organization (CDSCO). “We expect the regulators and the government as a whole to have a much better appreciation of fundamental drug research and make more enabling policies for us,” mentioned Dr. Khorakiwala.
Accessibility and affordability are different necessary components in the improvement of new antibiotics. Wockhardt’s technique is to value its medicine based mostly on the buying energy of completely different nations. For instance, the value of a drug in India may very well be up to 80% lower than the value in the United States. “Accessibility is as important as finding a new drug”, added Dr. Khorakiwala.
For Vysakh, the problem is deeply private. His story is a reminder of the harsh actuality of AMR – a silent menace unnoticed by many. And his expertise sheds mild on the challenges households face in healthcare amenities in India. “I would really love to see two major changes – diagnostics and proper quality control for the equipment used,” he mentioned. He additionally believes schooling has to be the first step in this combat in opposition to AMR together with stringent rules round the distribution of antibiotics.
Emerging resistance to newer formulations
Infectious ailments specialists have additionally flagged rising resistance to newer drug formulations too, extra just lately. Abdul Ghafur, founder, AMR Declaration Trust, in a letter to the Drugs Controller General of India cautioned that misuse of newer molecules is main to preliminary indicators of resistance as reported by The Hindu. Ceftazidime-avibactam. a brand new and potent antibiotic, he claimed, is shedding efficacy due to in depth, irrational, and uncontrolled use. The drug, which was initially registered with the U.S. FDA in 2015 and authorised in India three years later, is a last-line antibiotic. It is to be used as focused remedy for sure carbapenem-resistant gram-negative infections and never prescribed as a broad spectrum antibiotic. Experts say that it’s greater than ever earlier than, necessary for the authorities to lead antibiotic stewardship, at this stage, as newer molecules are lastly enter the market.
Addressing AMR is now not elective and tackling it requires a multifaceted strategy with a shared sense of accountability to make a distinction. “Combating AMR is not just a scientific or medical challenge, it is a collective responsibility that requires coordinated action across sectors, as well as sustained investment and empowered communities,” mentioned Dr. Mestrovic. “We have the right tools, knowledge and innovation to make a difference, but success depends on translating awareness into action at every level – from policymakers and researchers to the medical community and the public.”
(Soujanya Padikkal is a contract content material supplier based mostly in Hyderabad. Email: souji_padikkal@yahoo.co.in)
Published – May 23, 2025 07:00 am IST
